A Phase 3 interventional study of Aripiprazole and Aripiprazole in Schizophrenia, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 52 sites in 7 countries. Open to participants aged 13 Years to 17 Years. Per ClinicalTrials.gov, last updated 2015-04-02.
Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 126 studies testing aripiprazole in Schizophrenia — 4 open to participants now, 4 under way, 1 of them phase 3. Aripiprazole · Schizophrenia.
Among the 126 studies testing aripiprazole in Schizophrenia, this one is the 41st largest by enrollment of the 125 interventional ones that give a count, is one of 4 that started in 2011, is one of 34 in phase 3, and was the 65th registered.
3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.
Browse Schizophrenia studies →4 of the 126 studies testing aripiprazole in Schizophrenia are open now, in 2 countries. Recruiting first, the newest first:
Minerva Neurosciences · Sites in United States
Ages 18–55
Northwell Health · Sites in United States, Canada
Ages 18–35
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Ages 18–65
Consorcio Centro de Investigación Biomédica en Red (CIBER)
Ages 15–40
By country, each count listing its studies:
Aripiprazole: first FDA approval 2002 (ABILIFY), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 13 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
126 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 10 · Phase 3 38 · Phase 4 56
First in 1998; this study’s year is marked. 4 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 252 is above the median of 70 across 2,951 interventional studies indexed under Schizophrenia.
Median enrollment 130 across the 125 interventional studies. Of the 105 that completed or were terminated, 47 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
66 of 126 have an industry lead sponsor. The 10 most frequent:
This study is registered under Otsuka Pharmaceutical Development & Commercialization, Inc., one of the names counted as Otsuka Holdings Co., Ltd.. Under that name alone:
Otsuka Pharmaceutical Development & Commercialization, Inc. is the lead sponsor of 297 studies on the registry; 19 are open to participants now.
Of its 106 completed or terminated interventional studies of FDA-regulated products, 71 (67%) have results posted.
120 studies in Schizophrenia by Otsuka Holdings Co., Ltd.: 3 open now, 4 under way, 3 of them phase 3. Of 111 finished, 64 (58%) have results posted.
Among the 120 studies in Schizophrenia by Otsuka Holdings Co., Ltd., this one is the 42nd largest by enrollment of the 111 interventional ones that give a count, is one of 9 that started in 2011, is one of 50 in phase 3, and was the 35th registered.
Otsuka Holdings Co., Ltd.’s Schizophrenia studies by the year they started, since 1998.
1 of the studies testing aripiprazole in Schizophrenia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07547384CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.Steady-state Bioequivalence Study of Aripiprazole for Injection in Patients With Schizophrenia. | 2027-09-05 |
Add it to your calendar (.ics) → With an account.
Among the 126 studies testing aripiprazole in Schizophrenia, from their registry updates:
Among Otsuka Holdings Co., Ltd.’s 120 in Schizophrenia:
This tab as a report to print or save as PDF → With an account.
This will be a randomized, double-blind, placebo-controlled study consisting of a screening period, a conversion phase (Phase 1), a stabilization phase (Phase 2), and a double-blind maintenance treatment phase (Phase 3), and a follow up period.
Subjects may be either outpatients or inpatients between screening and through the time they reach stabilization at the end of Phase 2; hospitalization is not a study requirement. However, eligible subjects must be outpatients at the beginning of Phase 3.
Subjects will be assessed weekly during Phase 1, weekly for the first 4 weeks of Phase 2 and 3, and biweekly for the remaining weeks during each of Phases 2 and 3. Subjects will be encouraged to call the investigators with any exacerbation of psychotic symptoms and/or any tolerability issues. The investigator will also have the option to phone the subjects and their guardian(s) at any time to ensure clinical stability.
A data monitoring committee (DMC) will provide oversight for safety monitoring and reviewing the interim analysis. One interim analysis is planned after 75% of the total expected number of impending relapse events (28 events) are achieved and will be conducted by an independent data analysis center. The DMC will make a recommendation about stopping or continuing the study based on safety and efficacy reviews. The results of the interim analysis and individual subject data will remain blinded to the sponsor during the course of the study until the DMC determines that the study will conclude based on the results of the interim analysis, or the study is completed after 37 endpoint events.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Aripiprazole (2-mg, 5-mg, 10-mg, 15-mg, 20-mg, 25-mg or 30-mg)
Drug: Aripiprazole
Aripiprazole (2-mg, 5-mg, 10-mg, 15-mg, 20-mg, 25-mg or 30-mg)
Drug: Aripiprazole
Aripiprazole (10-mg, 15-mg, 20-mg, 25-mg or 30-mg) or placebo
Drug: Aripiprazole
Aripiprazole (2-mg, 5-mg, 10-mg, 15-mg, 20-mg, 25-mg or 30-mg)
Aripiprazole (10-mg, 15-mg, 20-mg, 25-mg or 30-mg)
Overall Relapse Rate (in Percent) From Randomization to Exacerbation of Psychotic Symptoms/Impending Relapse.
The primary efficacy variable was overall relapse rate from randomization, as assessed by Clinical Global Impression of Improvement (CGI-I) score ≥5, Positive and Negative Syndrome Scale (PANSS) scores for hostility or uncooperativeness ≥5, or ≥20% increase in PANSS Total Score. Impending relapse was defined as meeting any of the following 5 criteria: 1) CGI-I score of ≥ 5 (minimally worse) and increase in individual PANSS items to a score \> 4 with an absolute increase of ≥ 2 on that specific item or absolute increase of ≥ 4 on the combined 4 PANSS items (conceptual disorganization, hallucinatory behavior, suspiciousness, unusual thought content). OR 2) CGI-I score of 6 or 7 (much or very much worse) OR 3) Hospitalization due to worsening of illness OR 4) Any suicidal behavior or answers of "yes" to Questions 4 or 5 on the suicidal ideation section of the C-SSRS OR 5) Violent or aggressive behavior resulting in clinically significant injury.
Time frame: Baseline to Week 52/End of Phase 3 visit.
Percentage of Participants Meeting Exacerbation of Psychotic Symptoms/Impending Relapse Criteria.
Impending relapse was defined as meeting any of the following 5 criteria: 1) CGI-I score of ≥ 5 (minimally worse) and increase in individual PANSS items to a score \> 4 with an absolute increase of ≥ 2 on that specific item or absolute increase of ≥ 4 on the combined 4 PANSS items. OR 2) CGI-I score of 6 or 7 (much or very much worse) OR 3) Hospitalization due to worsening of illness OR 4) Any suicidal behavior or answers of "yes" to Questions 4 or 5 on the suicidal ideation section of the C-SSRS OR 5) Violent or aggressive behavior resulting in clinically significant injury.
Time frame: Baseline to Week 52/End of Phase 3 visit.
Percentage of Responders in Each Treatment Group.
Percentage of responders in each treatment group (i.e, response defined as meeting stability criteria). Participants stabilized on aripiprazole (trial drug) within the approved dose range of 10 to 30 mg/day and are tolerable based on clinical judgment.
Time frame: Baseline to Week 52/End of Phase 3 visit
Percentage of Participants Who Had Achieved Remission.
Percentage of participants who had achieved remission, where remission was defined as a score of ≤ 3 on each of the following specific PANSS items, maintained for a period of 6 months: delusions, unusual thought content, hallucinatory behavior, conceptual disorganization, mannerisms/ posturing, blunted affect, social withdrawal, and lack of spontaneity.
Time frame: Baseline to Week 52/End of Phase 3 visit.
Percentage of Participants Who Discontinued Due to All Reasons Other Than Sponsor Discontinued Study.
Percentage of participants discontinued due to all reasons other than sponsor discontinued study were noted.
Time frame: Baseline to Week 52/End of Phase 3 visit
Mean Change From Baseline to Endpoint in PANSS Total Score.
The PANSS consisted of 3 subscales with a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 indicates (absence of symptoms) and a score of 7 indicates (extremely severe symptoms). The symptom constructs for each subscale were positive subscale, negative subscale and general psychopathology subscale. The PANSS Total Score ranged from 30 (best possible outcome) to 210 (worst possible outcome).
Time frame: Baseline to Week 52/End of Phase 3 visit.
Mean Change From Baseline to Endpoint in CGI-S Score.
The severity of illness for each participant was rated using the CGI-S scale. To assess CGI-s, the Investigator answered the following question: "Considering your total clinical experience with this particular population, how mentally ill is the participant at this time?" Response choices included: 0= not assessed; 1= normal, not at all ill; 2= borderline mentally ill; 3= mildly ill; 4= moderately ill; 5= markedly ill; 6= severely ill; and 7= among the most extremely ill participants.
Time frame: Baseline to Week 52/End of Phase 3 visit.
Mean CGI-I Score at Endpoint.
Baseline for the double-blind maintenance phase was defined as the last visit with available data in the stabilization phase, and the CGI-I scale was completed prior to or on the first dose date in the double-blind maintenance phase. Response choices included: 0 = not assessed; 1 = very much improved,;2 = much improved; 3 = minimally improved; 4 = no change; 5 = minimally worse; 6 = much worse; and 7 = very much worse.
Time frame: Baseline to Week 52/End of Phase 3 visit.
Mean Change From Baseline to Endpoint in PANSS Positive Subscale.
The PANSS consisted of 3 subscales were a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 indicated (absence of symptoms) and a score of 7 indicated (extremely severe symptoms). The 7 positive symptom constructs were delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness/persecution, and hostility. The PANSS Total Score ranged from 30 (best possible outcome) to 210 (worst possible outcome).
Time frame: Baseline to Week 52/End of Phase 3 visit.
Mean Change From Baseline to Endpoint in PANSS Negative Subscale.
The PANSS consisted of 3 subscales were a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 indicated (absence of symptoms) and a score of 7 indicated (extremely severe symptoms). The 7 negative symptom constructs were blunted affect, emotional withdrawal, poor rapport, passive apathetic withdrawal, difficulty in abstract thinking, lack of spontaneity and flow of conversation and stereotyped thinking. The PANSS Total Score ranged from 30 (best possible outcome) to 210 (worst possible outcome).
Time frame: Baseline to Week 52/End of Phase 3 visit.
Mean Change From Baseline to Endpoint in Children's Global Assessment Scale (CGAS).
The CGAS was developed by Schaffer and colleagues to provide a global measure of severity of disturbance in children and adolescents. The CGAS is a rating scale for evaluating the overall functioning of a participant during a specified time period on a continuum from psychological or psychiatric sickness to health. The CGAS is a valid and reliable tool for rating a child's general level of functioning on a health-illness continuum. CGAS score (range 1-100) was a single item score for rating a child's general level of functioning on a health-illness continuum, with higher scores represented better functioning.
Time frame: Baseline to Week 52/End of Phase 3 visit.
A Phase 3 randomized, double-blind, placebo-controlled study consisted of screening period, conversion (Period 1), stabilization (Period 2), double-blind maintenance treatment (Period 3) and a follow-up period to evaluate efficacy and safety of aripiprazole (10-30 mg/day) compared to placebo in adolescent participants with schizophrenia.
| Milestone | Aripiprazole-Conversion Phase | Aripiprazole-Stabilization Phase | Aripiprazole-Double Blind (DB) Maintenance | Aripiprazole-Placebo-DB Maintenance |
|---|---|---|---|---|
| Started | 186 | 0 | 0 | 0 |
| Completed | 168 | 0 | 0 | 0 |
| Not completed | 18 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 | 0 |
| Withdrew: Sponsor discontinued trial | 4 | 0 | 0 | 0 |
| Withdrew: Met withdrawal criteria | 1 | 0 | 0 | 0 |
| Withdrew: Physician decision | 2 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 7 | 0 | 0 | 0 |
| Withdrew: Adverse event without relapse | 3 | 0 | 0 | 0 |
| Milestone | Aripiprazole-Conversion Phase | Aripiprazole-Stabilization Phase | Aripiprazole-Double Blind (DB) Maintenance | Aripiprazole-Placebo-DB Maintenance |
|---|---|---|---|---|
| Started | 0 | 183 | 0 | 0 |
| Completed | 0 | 146 | 0 | 0 |
| Not completed | 0 | 37 | 0 | 0 |
| Withdrew: Sponsor discontinued trial | 0 | 16 | 0 | 0 |
| Withdrew: Met withdrawal criteria | 0 | 7 | 0 | 0 |
| Withdrew: Physician decision | 0 | 3 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 5 | 0 | 0 |
| Withdrew: Adverse event without relapse | 0 | 6 | 0 | 0 |
| Milestone | Aripiprazole-Conversion Phase | Aripiprazole-Stabilization Phase | Aripiprazole-Double Blind (DB) Maintenance | Aripiprazole-Placebo-DB Maintenance |
|---|---|---|---|---|
| Started | 0 | 0 | 98 | 48 |
| Completed | 0 | 0 | 15 | 6 |
| Not completed | 0 | 0 | 83 | 42 |
| Withdrew: Sponsor discontinued trial | 0 | 0 | 58 | 19 |
| Withdrew: Physician decision | 0 | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 4 | 4 |
| Withdrew: Adverse event without relapse | 0 | 0 | 1 | 1 |
| Withdrew: Relapse with ae | 0 | 0 | 19 | 18 |
The primary efficacy variable was overall relapse rate from randomization, as assessed by Clinical Global Impression of Improvement (CGI-I) score ≥5, Positive and Negative Syndrome Scale (PANSS) scores for hostility or uncooperativeness ≥5, or ≥20% increase in PANSS Total Score. Impending relapse was defined as meeting any of the following 5 criteria: 1) CGI-I score of ≥ 5 (minimally worse) and increase in individual PANSS items to a score \> 4 with an absolute increase of ≥ 2 on that specific item or absolute increase of ≥ 4 on the combined 4 PANSS items (conceptual disorganization, hallucinatory behavior, suspiciousness, unusual thought content). OR 2) CGI-I score of 6 or 7 (much or very much worse) OR 3) Hospitalization due to worsening of illness OR 4) Any suicidal behavior or answers of "yes" to Questions 4 or 5 on the suicidal ideation section of the C-SSRS OR 5) Violent or aggressive behavior resulting in clinically significant injury.
| relapse rate(percentage of participants) | Aripiprazole-Double Blind Maintenance | Placebo-Double Blind Maintenance |
|---|---|---|
| Overall Relapse Rate (in Percent) From Randomization to Exacerbation of Psychotic Symptoms/Impending Relapse. | 19.39 | 37.50 |
Impending relapse was defined as meeting any of the following 5 criteria: 1) CGI-I score of ≥ 5 (minimally worse) and increase in individual PANSS items to a score \> 4 with an absolute increase of ≥ 2 on that specific item or absolute increase of ≥ 4 on the combined 4 PANSS items. OR 2) CGI-I score of 6 or 7 (much or very much worse) OR 3) Hospitalization due to worsening of illness OR 4) Any suicidal behavior or answers of "yes" to Questions 4 or 5 on the suicidal ideation section of the C-SSRS OR 5) Violent or aggressive behavior resulting in clinically significant injury.
| percentage of participants | Aripiprazole-Double Blind Maintenance | Placebo-Double Blind Maintenance |
|---|---|---|
| CGI-I + PANSS | 16.33 | 33.33 |
| CGI-I of 6 or 7 | 11.22 | 25.00 |
| Hospitalization | 1.02 | 10.42 |
| Suicidal Behavior | 1.02 | 0.00 |
| Violent Behavior | 4.08 | 10.42 |
Percentage of responders in each treatment group (i.e, response defined as meeting stability criteria). Participants stabilized on aripiprazole (trial drug) within the approved dose range of 10 to 30 mg/day and are tolerable based on clinical judgment.
| percentage of participants | Aripiprazole-Double Blind Maintenance | Placebo-Double Blind Maintenance |
|---|---|---|
| Week 1 (Arirpiprazole N= 95, Placebo N= 45) | 96.8 | 97.8 |
| Week 2 (N= 91, 46) | 92.3 | 95.7 |
| Week 3 (N= 86, 45) | 93.0 | 86.7 |
| Week 4 (N= 91, 43) | 93.4 | 90.7 |
| Week 6 (N= 87, 41) | 90.8 | 92.7 |
| Week 8 (N= 82, 38) | 97.6 | 89.5 |
| Week 10 (N= 74, 32) | 94.6 | 93.8 |
| Week 12 (N= 71, 30) | 94.4 | 93.3 |
| Week 14 (N= 68, 26) | 94.1 | 92.3 |
| Week 16 (N= 65, 25) | 96.9 | 96.0 |
| Week 18 (N= 59, 23) | 94.9 | 91.3 |
| Week 20 (N= 57, 23) | 94.7 | 91.3 |
| Week 22 (N= 55, 21) | 92.7 | 95.2 |
| Week 24 (N= 51, 19) | 98.0 | 100.0 |
| Week 26 (N= 48, 19) | 97.9 | 100.0 |
| Week 28 (N= 42, 17) | 97.6 | 100.0 |
| Week 30 (N= 40, 16) | 95.0 | 100.0 |
| Week 32 (N= 39, 16) | 94.9 | 93.8 |
| Week 34 (N= 38, 14) | 94.7 | 100.0 |
| Week 36 (N= 36, 15) | 94.4 | 100.0 |
| Week 38 (N= 33, 12) | 100.0 | 100.0 |
| Week 40 (N= 29, 11) | 100.0 | 100.0 |
| Week 42 (N= 27, 11) | 100.0 | 100.0 |
| Week 44 (N= 21, 8) | 100.0 | 100.0 |
| Week 46 (N= 18, 8) | 88.9 | 100.0 |
| Week 48 (N= 17, 8) | 94.1 | 100.0 |
| Week 50 (N= 17, 6) | 88.2 | 100.0 |
| Week 52 (N= 14, 7) | 100.0 | 100.0 |
| Last Visit (N= 98, 48) | 77.6 | 64.6 |
Percentage of participants who had achieved remission, where remission was defined as a score of ≤ 3 on each of the following specific PANSS items, maintained for a period of 6 months: delusions, unusual thought content, hallucinatory behavior, conceptual disorganization, mannerisms/ posturing, blunted affect, social withdrawal, and lack of spontaneity.
| percentage of participants | Aripiprazole-Double Blind Maintenance | Placebo-Double Blind Maintenance |
|---|---|---|
| Percentage of Participants Who Had Achieved Remission. | 43.8 | 42.1 |
Percentage of participants discontinued due to all reasons other than sponsor discontinued study were noted.
| percentage of participants | Aripiprazole-Double Blind Maintenance | Placebo-Double Blind Maintenance |
|---|---|---|
| Percentage of Participants Who Discontinued Due to All Reasons Other Than Sponsor Discontinued Study. | 25.51 | 47.92 |
The PANSS consisted of 3 subscales with a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 indicates (absence of symptoms) and a score of 7 indicates (extremely severe symptoms). The symptom constructs for each subscale were positive subscale, negative subscale and general psychopathology subscale. The PANSS Total Score ranged from 30 (best possible outcome) to 210 (worst possible outcome).
| Units on a scale | Aripiprazole-Double Blind Maintenance | Placebo-Double Blind Maintenance |
|---|---|---|
| Week 1 (Aripiprazole N= 95, Placebo N= 45) | 0.22 ± 5.62 | -0.27 ± 4.66 |
| Week 2 | 0.09 ± 5.77 | -0.58 ± 6.01 |
| Week 3 | -0.36 ± 6.41 | 1.81 ± 9.66 |
| Week 4 | -0.64 ± 6.90 | 1.56 ± 11.13 |
| Week 6 | -1.20 ± 8.28 | 2.92 ± 13.39 |
| Week 8 | -1.62 ± 9.20 | 3.71 ± 14.29 |
| Week 10 | -1.20 ± 9.61 | 3.90 ± 14.80 |
| Week 12 | -0.19 ± 10.57 | 4.52 ± 16.17 |
| Week 14 | -0.18 ± 11.06 | 5.50 ± 17.21 |
| Week 16 | -0.78 ± 11.72 | 5.56 ± 17.33 |
| Week 18 | -0.68 ± 12.30 | 5.57 ± 17.24 |
| Week 20 | -0.57 ± 12.46 | 6.06 ± 17.84 |
| Week 22 | -0.31 ± 12.37 | 6.10 ± 18.98 |
| Week 24 | -0.36 ± 12.36 | 5.92 ± 19.22 |
| Week 26 | -0.88 ± 12.41 | 5.81 ± 19.65 |
| Week 28 | -0.85 ± 12.52 | 5.65 ± 19.82 |
| Week 30 | -0.96 ± 12.71 | 5.60 ± 19.96 |
| Week 32 | -0.99 ± 12.74 | 6.21 ± 20.43 |
| Week 34 | -1.12 ± 13.05 | 5.79 ± 19.85 |
| Week 36 | -0.55 ± 13.04 | 5.40 ± 20.20 |
| Week 38 | -0.84 ± 13.17 | 5.21 ± 20.27 |
| Week 40 | -0.92 ± 13.21 | 5.10 ± 20.34 |
| Week 42 | -1.14 ± 13.26 | 4.94 ± 20.36 |
| Week 44 | -0.96 ± 13.32 | 4.88 ± 20.47 |
| Week 46 | -1.02 ± 13.35 | 4.83 ± 20.54 |
| Week 48 | -0.99 ± 13.34 | 4.67 ± 20.72 |
| Week 50 | -1.19 ± 13.43 | 4.71 ± 20.66 |
| Week 52 | -1.31 ± 13.47 | 4.79 ± 20.60 |
The severity of illness for each participant was rated using the CGI-S scale. To assess CGI-s, the Investigator answered the following question: "Considering your total clinical experience with this particular population, how mentally ill is the participant at this time?" Response choices included: 0= not assessed; 1= normal, not at all ill; 2= borderline mentally ill; 3= mildly ill; 4= moderately ill; 5= markedly ill; 6= severely ill; and 7= among the most extremely ill participants.
| Units on a scale | Aripiprazole-Double Blind Maintenance | Placebo-Double Blind Maintenance |
|---|---|---|
| Week 1 (Aripiprazole N= 94, Placebo N= 45) | 0.01 ± 0.23 | 0.02 ± 0.34 |
| Week 2 (N= 97, 48) | 0.00 ± 0.32 | 0.02 ± 0.44 |
| Week 3 | 0.01 ± 0.40 | 0.13 ± 0.64 |
| Week 4 | 0.03 ± 0.44 | 0.10 ± 0.69 |
| Week 6 | 0.04 ± 0.52 | 0.15 ± 0.77 |
| Week 8 | 0.04 ± 0.63 | 0.19 ± 0.79 |
| Week 10 | 0.02 ± 0.71 | 0.25 ± 0.81 |
| Week 12 | 0.05 ± 0.77 | 0.31 ± 0.85 |
| Week 14 | 0.03 ± 0.78 | 0.35 ± 1.04 |
| Week 16 | 0.02 ± 0.83 | 0.33 ± 1.06 |
| Week 18 | 0.04 ± 0.83 | 0.35 ± 1.06 |
| Week 20 | 0.05 ± 0.85 | 0.40 ± 1.12 |
| Week 22 | 0.08 ± 0.87 | 0.38 ± 1.14 |
| Week 24 | 0.06 ± 0.88 | 0.35 ± 1.18 |
| Week 26 | 0.05 ± 0.89 | 0.35 ± 1.18 |
| Week 28 | 0.05 ± 0.92 | 0.33 ± 1.19 |
| Week 30 | 0.04 ± 0.91 | 0.33 ± 1.19 |
| Week 32 | 0.04 ± 0.92 | 0.31 ± 1.21 |
| Week 34 | 0.05 ± 0.93 | 0.29 ± 1.22 |
| Week 36 | 0.07 ± 0.95 | 0.29 ± 1.22 |
| Week 38 | 0.07 ± 0.95 | 0.29 ± 1.22 |
| Week 40 | 0.07 ± 0.95 | 0.29 ± 1.22 |
| Week 42 | 0.06 ± 0.94 | 0.29 ± 1.22 |
| Week 44 | 0.08 ± 0.95 | 0.31 ± 1.21 |
| Week 46 | 0.07 ± 0.95 | 0.31 ± 1.21 |
| Week 48 | 0.06 ± 0.94 | 0.29 ± 1.22 |
| Week 50 | 0.05 ± 0.95 | 0.27 ± 1.25 |
| Week 52 | 0.05 ± 0.95 | 0.29 ± 1.22 |
Baseline for the double-blind maintenance phase was defined as the last visit with available data in the stabilization phase, and the CGI-I scale was completed prior to or on the first dose date in the double-blind maintenance phase. Response choices included: 0 = not assessed; 1 = very much improved,;2 = much improved; 3 = minimally improved; 4 = no change; 5 = minimally worse; 6 = much worse; and 7 = very much worse.
| Units on a scale | Aripiprazole-Double Blind Maintenance | Placebo-Double Blind Maintenance |
|---|---|---|
| Baseline | 2.40 ± 0.80 | 2.52 ± 0.82 |
| Week 1 (Aripiprazole N= 94, Placebo N= 45) | 3.49 ± 0.84 | 3.51 ± 0.84 |
| Week 2 (N= 97, 48) | 3.48 ± 0.88 | 3.52 ± 0.95 |
| Week 3 | 3.47 ± 0.89 | 3.63 ± 1.06 |
| Week 4 | 3.60 ± 0.92 | 3.60 ± 1.20 |
| Week 6 | 3.53 ± 1.00 | 3.73 ± 1.30 |
| Week 8 | 3.46 ± 1.09 | 3.83 ± 1.45 |
| Week 10 | 3.38 ± 1.13 | 3.90 ± 1.49 |
| Week 12 | 3.45 ± 1.19 | 3.96 ± 1.44 |
| Week 14 | 3.44 ± 1.23 | 4.04 ± 1.56 |
| Week 16 | 3.32 ± 1.25 | 4.00 ± 1.57 |
| Week 18 | 3.35 ± 1.29 | 4.02 ± 1.58 |
| Week 20 | 3.40 ± 1.30 | 4.08 ± 1.54 |
| Week 22 | 3.43 ± 1.34 | 4.04 ± 1.60 |
| Week 24 | 3.41 ± 1.31 | 4.06 ± 1.60 |
| Week 26 | 3.41 ± 1.34 | 4.06 ± 1.60 |
| Week 28 | 3.43 ± 1.34 | 4.02 ± 1.64 |
| Week 30 | 3.44 ± 1.36 | 4.00 ± 1.66 |
| Week 32 | 3.46 ± 1.37 | 3.98 ± 1.68 |
| Week 34 | 3.47 ± 1.36 | 3.94 ± 1.71 |
| Week 36 | 3.48 ± 1.39 | 3.94 ± 1.71 |
| Week 38 | 3.45 ± 1.38 | 3.94 ± 1.71 |
| Week 40 | 3.45 ± 1.38 | 3.92 ± 1.72 |
| Week 42 | 3.45 ± 1.38 | 3.92 ± 1.72 |
| Week 44 | 3.45 ± 1.38 | 3.94 ± 1.71 |
| Week 46 | 3.46 ± 1.37 | 3.94 ± 1.71 |
| Week 48 | 3.46 ± 1.38 | 3.92 ± 1.72 |
| Week 50 | 3.43 ± 1.38 | 3.92 ± 1.72 |
| Week 52 | 3.42 ± 1.39 | 3.92 ± 1.72 |
The PANSS consisted of 3 subscales were a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 indicated (absence of symptoms) and a score of 7 indicated (extremely severe symptoms). The 7 positive symptom constructs were delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness/persecution, and hostility. The PANSS Total Score ranged from 30 (best possible outcome) to 210 (worst possible outcome).
| Units on a scale | Aripiprazole-Double Blind Maintenance | Placebo-Double Blind Maintenance |
|---|---|---|
| Week 1 (Aripiprazole N= 95, Placebo N= 45) | 0.08 ± 1.84 | 0.07 ± 2.41 |
| Week 2 | 0.09 ± 2.05 | -0.04 ± 2.87 |
| Week 3 | 0.01 ± 2.36 | 0.56 ± 3.34 |
| Week 4 | -0.12 ± 2.65 | 0.58 ± 3.80 |
| Week 6 | -0.20 ± 2.90 | 1.10 ± 4.85 |
| Week 8 | -0.19 ± 3.23 | 1.56 ± 5.11 |
| Week 10 | -0.16 ± 3.28 | 1.63 ± 5.45 |
| Week 12 | 0.23 ± 3.58 | 1.96 ± 5.78 |
| Week 14 | 0.28 ± 3.77 | 2.27 ± 6.03 |
| Week 16 | 0.32 ± 3.77 | 2.17 ± 6.05 |
| Week 18 | 0.24 ± 3.98 | 2.15 ± 6.14 |
| Week 20 | 0.18 ± 4.00 | 2.44 ± 6.32 |
| Week 22 | 0.39 ± 4.12 | 2.60 ± 6.44 |
| Week 24 | 0.38 ± 4.23 | 2.65 ± 6.36 |
| Week 26 | 0.22 ± 4.23 | 2.58 ± 6.45 |
| Week 28 | 0.17 ± 4.28 | 2.56 ± 6.51 |
| Week 30 | 0.24 ± 4.43 | 2.60 ± 6.59 |
| Week 32 | 0.22 ± 4.41 | 2.71 ± 6.64 |
| Week 34 | 0.18 ± 4.45 | 2.58 ± 6.54 |
| Week 36 | 0.29 ± 4.45 | 2.48 ± 6.60 |
| Week 38 | 0.22 ± 4.55 | 2.46 ± 6.63 |
| Week 40 | 0.27 ± 4.56 | 2.44 ± 6.69 |
| Week 42 | 0.24 ± 4.52 | 2.35 ± 6.73 |
| Week 44 | 0.27 ± 4.52 | 2.33 ± 6.76 |
| Week 46 | 0.21 ± 4.52 | 2.42 ± 6.69 |
| Week 48 | 0.30 ± 4.53 | 2.29 ± 6.77 |
| Week 50 | 0.20 ± 4.52 | 2.33 ± 6.75 |
| Week 52 | 0.16 ± 4.55 | 2.31 ± 6.77 |
The PANSS consisted of 3 subscales were a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 indicated (absence of symptoms) and a score of 7 indicated (extremely severe symptoms). The 7 negative symptom constructs were blunted affect, emotional withdrawal, poor rapport, passive apathetic withdrawal, difficulty in abstract thinking, lack of spontaneity and flow of conversation and stereotyped thinking. The PANSS Total Score ranged from 30 (best possible outcome) to 210 (worst possible outcome).
| Units on a scale | Aripiprazole-Double Blind Maintenance | Placebo-Double Blind Maintenance |
|---|---|---|
| Week 1 (Aripiprazole N= 95, Placebo N= 45) | 0.03 ± 1.57 | -0.09 ± 1.40 |
| Week 2 | -0.07 ± 1.68 | -0.23 ± 2.35 |
| Week 3 | -0.39 ± 1.89 | 0.48 ± 3.17 |
| Week 4 | -0.27 ± 2.12 | 0.44 ± 3.41 |
| Week 6 | -0.42 ± 2.37 | 0.90 ± 3.57 |
| Week 8 | -0.41 ± 2.37 | 0.77 ± 3.76 |
| Week 10 | -0.33 ± 2.47 | 0.71 ± 3.82 |
| Week 12 | -0.38 ± 2.91 | 0.79 ± 4.47 |
| Week 14 | -0.41 ± 3.13 | 1.15 ± 4.63 |
| Week 16 | -0.51 ± 3.31 | 1.19 ± 4.77 |
| Week 18 | -0.47 ± 3.45 | 1.19 ± 4.75 |
| Week 20 | -0.47 ± 3.54 | 1.10 ± 4.93 |
| Week 22 | -0.43 ± 3.55 | 1.06 ± 5.26 |
| Week 24 | -0.42 ± 3.54 | 0.79 ± 5.41 |
| Week 26 | -0.54 ± 3.60 | 0.81 ± 5.43 |
| Week 28 | -0.51 ± 3.63 | 0.83 ± 5.43 |
| Week 30 | -0.56 ± 3.57 | 0.67 ± 5.55 |
| Week 32 | -0.52 ± 3.60 | 0.98 ± 5.89 |
| Week 34 | -0.64 ± 3.68 | 0.56 ± 5.61 |
| Week 36 | -0.47 ± 3.71 | 0.65 ± 5.69 |
| Week 38 | -0.62 ± 3.70 | 0.54 ± 5.84 |
| Week 40 | -0.64 ± 3.78 | 0.54 ± 5.78 |
| Week 42 | -0.77 ± 3.79 | 0.42 ± 5.75 |
| Week 44 | -0.72 ± 3.87 | 0.46 ± 5.76 |
| Week 46 | -0.68 ± 3.84 | 0.35 ± 5.83 |
| Week 48 | -0.73 ± 3.83 | 0.33 ± 5.88 |
| Week 50 | -0.80 ± 3.84 | 0.29 ± 5.96 |
| Week 52 | -0.78 ± 3.81 | 0.40 ± 5.87 |
The CGAS was developed by Schaffer and colleagues to provide a global measure of severity of disturbance in children and adolescents. The CGAS is a rating scale for evaluating the overall functioning of a participant during a specified time period on a continuum from psychological or psychiatric sickness to health. The CGAS is a valid and reliable tool for rating a child's general level of functioning on a health-illness continuum. CGAS score (range 1-100) was a single item score for rating a child's general level of functioning on a health-illness continuum, with higher scores represented better functioning.
| Units on a scale | Aripiprazole-Double Blind Maintenance | Placebo-Double Blind Maintenance |
|---|---|---|
| Week 1 (Aripiprazole N= 95, Placebo N= 45) | 0.00 ± 2.74 | -0.09 ± 2.02 |
| Week 2 | -0.10 ± 3.90 | -0.31 ± 4.03 |
| Week 3 | 0.35 ± 4.36 | -1.04 ± 7.21 |
| Week 4 | 0.29 ± 5.22 | -1.23 ± 7.78 |
| Week 6 | 0.40 ± 6.01 | -2.08 ± 9.14 |
| Week 8 | 0.98 ± 6.90 | -2.40 ± 9.93 |
| Week 10 | 1.11 ± 7.47 | -2.31 ± 11.63 |
| Week 12 | 1.08 ± 8.21 | -2.85 ± 11.40 |
| Week 14 | 1.06 ± 8.49 | -3.52 ± 12.40 |
| Week 16 | 1.57 ± 8.69 | -2.69 ± 12.96 |
| Week 18 | 1.55 ± 9.41 | -2.90 ± 13.07 |
| Week 20 | 1.28 ± 9.88 | -4.06 ± 14.84 |
| Week 22 | 1.17 ± 10.15 | -3.77 ± 15.05 |
| Week 24 | 1.33 ± 10.33 | -3.67 ± 15.20 |
| Week 26 | 1.61 ± 10.37 | -3.69 ± 15.29 |
| Week 28 | 1.73 ± 10.73 | -3.75 ± 15.26 |
| Week 30 | 1.92 ± 10.89 | -3.44 ± 15.45 |
| Week 32 | 1.86 ± 11.03 | -3.33 ± 15.47 |
| Week 34 | 2.05 ± 11.19 | -3.00 ± 15.85 |
| Week 36 | 1.87 ± 11.41 | -3.10 ± 15.70 |
| Week 38 | 2.00 ± 11.59 | -2.85 ± 15.95 |
| Week 40 | 1.90 ± 11.68 | -2.85 ± 15.99 |
| Week 42 | 1.90 ± 11.74 | -2.69 ± 16.17 |
| Week 44 | 1.83 ± 11.86 | -2.67 ± 16.18 |
| Week 46 | 2.13 ± 11.74 | -2.67 ± 16.17 |
| Week 48 | 2.17 ± 11.79 | -2.40 ± 16.42 |
| Week 50 | 2.29 ± 11.74 | -2.31 ± 16.51 |
| Week 52 | 2.35 ± 11.85 | -2.25 ± 16.58 |
Collected over AEs were recorded from the time the ICF was signed (with 4-Week Post-Trial Follow-up).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Aripiprazole-Conversion Phase | — | 0/186 (0%) | 52/186 (28%) |
| Arpiprazole-Stabilization Phase | — | 4/183 (2.2%) | 56/183 (30.6%) |
| Aripiprazole-Double Blind Maintenance Treatment | — | 3/98 (3.1%) | 41/98 (41.8%) |
| Placebo-Double Blind Maintenance Treatment | — | 6/48 (12.5%) | 25/48 (52.1%) |
| Event | Aripiprazole-Conversion Phase | Arpiprazole-Stabilization Phase | Aripiprazole-Double Blind Maintenance Treatment | Placebo-Double Blind Maintenance Treatment |
|---|---|---|---|---|
| SchizophreniaPsychiatric disorders | 0/186 | 2/183 | 1/98 | 5/48 |
| Psychotic disorderPsychiatric disorders | 0/186 | 1/183 | 2/98 | 1/48 |
| NeutropeniaBlood and lymphatic system disorders | 0/186 | 1/183 | 0/98 | 0/48 |
| Event | Aripiprazole-Conversion Phase | Arpiprazole-Stabilization Phase | Aripiprazole-Double Blind Maintenance Treatment | Placebo-Double Blind Maintenance Treatment |
|---|---|---|---|---|
| InsomniaPsychiatric disorders | 16/186 | 14/183 | 5/98 | 9/48 |
| SchizophreniaPsychiatric disorders | 0/186 | 0/183 | 9/98 | 8/48 |
| Weight increasedInvestigations | 0/186 | 13/183 | 8/98 | 5/48 |
| SomnolenceNervous system disorders | 19/186 | 12/183 | 0/98 | 0/48 |
| HeadacheNervous system disorders | 12/186 | 13/183 | 6/98 | 4/48 |
| Psychotic disorderPsychiatric disorders | 0/186 | 0/183 | 7/98 | 4/48 |
| TremorNervous system disorders | 0/186 | 13/183 | 4/98 | 4/48 |
| AkathisiaNervous system disorders | 11/186 | 14/183 | 3/98 | 3/48 |
| NasopharyngitisInfections and infestations | 0/186 | 0/183 | 7/98 | 1/48 |
| NauseaGastrointestinal disorders | 0/186 | 0/183 | 1/98 | 3/48 |
| Age, Continuous(Years) | Aripiprazole-Double Blind Maintenance | Placebo-Double Blind Maintenance | Total |
|---|---|---|---|
| Male | 15.3 ± 1.3 | 15.6 ± 1.1 | 15.4 ± 1.2 |
| Female | 15.4 ± 1.1 | 15.3 ± 1.0 | 15.3 ± 1.1 |
| Sex: Female, Male(Participants) | Aripiprazole-Double Blind Maintenance | Placebo-Double Blind Maintenance | Total |
|---|---|---|---|
| Female | 36 | 14 | 50 |
| Male | 62 | 34 | 96 |
The record gives a start of Jul 2011, a primary completion of Nov 2013 and a completion of Dec 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2015, 1 year 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Aripiprazole
Otsuka Pharmaceutical Development & Commercialization, Inc. →